AZ says Calquence is a safer drug than Imbruvica

AZ says Calquence is a safer drug than Imbruvica

Source: 
Pharmaforum
snippet: 

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment of chronic lymphocytic leukaemia (CLL). Now, AZ has new data suggesting its drug is less likely to cause a serious cardiac side effect.